Exhibit 99.1 Average PMPM Fees/ Revenue per Case Evolent Announces Second Quarter 2024 Results • Revenue of $647.1 million, an increase of $178.0 million or 37.9%, from the three months ended June 30, 2023. • Net loss attributable to common shareholders of Evolent Health, Inc. of $(6.4) million and a net loss margin of (1.0)%. • Adjusted EBITDA of $52.0 million resulting in an Adjusted EBITDA margin of 8.0%. • Narrows revenue outlook for full year 2024 and provides updated 2024 Adjusted EBITDA guidance. • R ...

Revenue of $647.1 million, an increase of $178.0 million or 37.9%, from the three months ended June 30, 2023. Net loss attributable to common shareholders of Evolent Health, Inc. of $(6.4) million and a net loss margin of (1.0)%. Adjusted EBITDA of $52.0 million resulting in an Adjusted EBITDA margin of 8.0%. Narrows revenue outlook for full year 2024 and provides updated 2024 Adjusted EBITDA guidance. Reiterates confidence in achieving $300 million in Adjusted EBITDA run rate exiting 2024. WASHINGTON, Aug. ...

Evolent Health (EVH) shares soared 12.8% in the last trading session to close at $21.72. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 11.1% loss over the past four weeks. This health care software and consulting services provider is expected to post quarterly earnings of $0.21 per share in its upcoming report, which represents a year-over-year change of +50%. Revenues are expected to be $634.18 million, up 35.2% from the year- ...

Company to Participate in Upcoming Conferences Analysts interested in asking questions during the live call should dial 855.940.9467, or 412.317.6034 for international callers, and reference the "Evolent call" 15 minutes prior to the call. Additionally, The Company announced that its executive management team will participate in upcoming investor conferences. About Evolent Seth R. Frank Vice President, Investor Relations Evolent [email protected] 571-895-3919 (W) Shareholders and interested participants may ...

Machinify is a privately held company based in Palo Alto, California. Upon closing, Evolent will be acquiring certain assets and the exclusive license to the Machinify Auth platform. In addition, certain employees of Machinify will be re-badged as Evolent employees upon closing. Lastly, Machinify and Evolent expect to enter into a long-term services agreement at closing to support the development and integration of the platform with Evolent. The acquisition is immaterial to Evolent's revenue outlook and is ...

Evolent Health (EVH) reported $639.65 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 49.6%. EPS of $0.34 for the same period compares to $0.21 a year ago.The reported revenue represents a surprise of +6.33% over the Zacks Consensus Estimate of $601.6 million. With the consensus EPS estimate being $0.21, the EPS surprise was +61.90%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall S ...

Financial Data and Key Metrics - Revenue for Q1 2024 totaled $639.7 million, a 49.6% year-over-year growth, exceeding the top end of the Q1 revenue guide of $610 million by almost $30 million [143] - Adjusted EBITDA for Q1 was $54.1 million, in line with the midpoint of the guidance [118] - The company raised the midpoint of its 2024 revenue guidance by $115 million and reiterated its adjusted EBITDA outlook of $235 million to $265 million [33] - Q1 gross margin was 16.4%, down 185 basis points sequentially versus Q4, driven by growth in performance suite products and higher unit medical expenses [156] Business Line Data and Key Metrics - The company signed seven new revenue agreements year-to-date, including three in Q1, with two being with Molina and one with a long-standing Medicaid health plan on the East Coast [4][23][31] - The performance suite risk business saw increased utilization in Q1, with lower data visibility than typical for this point in the year [6] - The company launched 25 Specialty Go Lives across multiple health plan customers for the performance suite and the technology and services suite [4] - The technology and services suite generated Q1 revenue of $89 million, representing underlying year-over-year growth of nearly 25% [10] Market Data and Key Metrics - The company's specialty care offerings now account for 91% of total revenue, up from 60% three years ago, with specialty care revenue growing approximately 69% year-over-year [139] - The company's presence with Molina will increase to nine states after the implementation of new solutions in South Carolina and Mississippi [29] - The company's average unique members in Q1 were 39.9 million, net of Medicaid redeterminations, with total product members eclipsing 80.6 million [28] Company Strategy and Industry Competition - The company is focused on organic growth, expanding profitability, and disciplined capital allocation, with a strong pipeline of new revenue agreements and successful go-lives [23][25] - The company is investing in artificial intelligence and patient navigation solutions to drive efficiency and improve care quality [24][141] - The company believes that the rising utilization environment creates significant opportunities for innovative solutions in specialty care management [121] Management Commentary on Operating Environment and Future Outlook - Management remains confident in the company's ability to drive long-term value creation, citing strong customer confidence and the ability to innovate and execute [9] - The company is taking a conservative approach to Q2 adjusted EBITDA guidance, with a range of $48 million to $62 million, due to lower claims visibility and elevated utilization indicators [13][126] - Management reiterated the 2024 exit run rate adjusted EBITDA target of $300 million and expects to achieve $150 million in cash flow from operations for the year [127][160] Other Important Information - The company successfully wound down the NIA transition services agreement in March, marking an important step towards achieving $15 million of NIA cost synergies [119] - The company announced a strategic partnership with Careology, a UK-based digital cancer care platform, to enhance patient navigation and care quality [141] - The company expects to implement new solutions in South Carolina and Mississippi by Q4 2024, contributing to the $4 million quarterly adjusted EBITDA earnings target [153] Q&A Session Summary Question: How is the macro payer landscape impacting the company's business? [44] - Answer: The macro payer landscape is creating significant pressure on health plans, driving increased interest in the company's specialty management solutions. This has added more opportunities to the sales funnel but may extend the sales cycle in some cases [44][18] Question: Can you provide more details on the contractual protections and rate adjustments? [131] - Answer: Contractual protections allow for rate adjustments based on population changes, with a 3 to 12-month lag. These adjustments are typically retrospective and vary by contract, depending on patient needs and contract structure [20][41] Question: How does the company view the impact of Medicaid redeterminations? [68] - Answer: Medicaid redeterminations have created a cumulative headwind of $5.5 million per quarter to adjusted EBITDA, consistent with expectations. The process is estimated to be over 80% complete as of Q1 2024 [123][68] Question: What is the outlook for gross margins and profitability? [75] - Answer: Gross margins are impacted by the mix between performance suite and tech and services products, with performance suite growth driving lower margins. The company expects gross margins to improve as new go-lives mature and cost efficiencies are realized [75][76] Question: How does the company plan to achieve its $300 million exit run rate adjusted EBITDA target? [82] - Answer: The company plans to achieve this target through performance suite maturation, new growth, and earnings from NIA and IPG. The company is on track to realize $8.75 million in quarterly NIA synergies by year-end [82][159] Question: What is the company's cash flow outlook for 2024? [92] - Answer: The company reaffirmed its expectation of $150 million or more in operating cash flow for the year, with Q1 in line with expectations and cash flow expected to build across the year [83][160]

Evolent Health (EVH) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of $0.21 per share. This compares to earnings of $0.21 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 61.90%. A quarter ago, it was expected that this health care software and consulting services provider would post earnings of $0.11 per share when it actually produced earnings of $0.23, delivering a surprise of 109. ...

Commission File Number: 001-37415 _________________________ Evolent Health, Inc. (Exact name of registrant as specified in its charter) _________________________ Delaware 32-0454912 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 1812 N. Moore Street , Suite 1705 , Arlington , Virginia 22209 (Address of principal executive offices) (Zip Code) (571) 389-6000 Registrant's telephone number, including area code _________________________ Securities registered p ...

Revenue Performance - Revenue for Q1 2024 was $639.7 million, an increase of $212.0 million or 49.6% compared to Q1 2023[3] - Revenue for Q1 2024 increased to $639.7 million, up 49.4% from $427.7 million in Q1 2023[21] - The company raised its revenue outlook for the full year 2024, expecting revenue between $2.53 billion and $2.60 billion[10] - For Q2 2024, revenue is expected to be in the range of approximately $625.0 million to $645.0 million[8] - The company reported a year-over-year growth of over 60% in specialty care revenue[3] Financial Metrics - Net loss attributable to common shareholders was $(25.2) million, with a net loss margin of (3.9)%[5] - Adjusted EBITDA for Q1 2024 was $54.1 million, resulting in an Adjusted EBITDA margin of 8.5%[5] - Adjusted income attributable to common shareholders was $38.5 million, with an adjusted income per share of $0.34[6] - Operating loss for Q1 2024 was $13.4 million, compared to a loss of $10.4 million in Q1 2023[21] - Net loss attributable to common shareholders decreased to $25.2 million in Q1 2024 from $26.3 million in Q1 2023[21] - Basic and diluted loss per common share improved to $(0.22) in Q1 2024 from $(0.24) in Q1 2023[21] - Adjusted income attributable to common shareholders for Q1 2024 was $38,507,000, compared to $22,140,000 in Q1 2023, representing a 74% increase[43] - Adjusted EBITDA for Q1 2024 was $54,097,000, with an adjusted EBITDA margin of 8.5%, down from $50,499,000 and 11.8% in Q1 2023[41] - Net loss attributable to common shareholders decreased to $25,225,000 in Q1 2024 from $26,258,000 in Q1 2023, resulting in a net loss margin improvement from (6.1)% to (3.9)%[41] Costs and Expenses - Cost of revenue for Q1 2024 was $535,547,000, up from $310,475,000 in Q1 2023, while adjusted cost of revenue was $534,542,000 compared to $308,243,000[38] - Selling, general and administrative expenses for Q1 2024 were $79,104,000, down from $89,726,000 in Q1 2023, with adjusted expenses at $51,014,000 compared to $68,948,000[39] - The company incurred repositioning costs of $1.8 million related to severance and professional services in Q1 2024[29] Cash and Assets - Total cash and cash equivalents as of March 31, 2024, was $165.1 million[5] - Cash and cash equivalents decreased to $165.1 million from $192.8 million at the end of 2023[23] - Total assets as of March 31, 2024, were $2.64 billion, down from $2.68 billion at the end of 2023[23] - Total current liabilities decreased slightly to $659.0 million from $674.2 million at the end of 2023[23] Market and Growth Strategy - Average Lives on Platform for the Performance Suite increased from 3,242 in Q1 2023 to 7,050 in Q1 2024[3] - New revenue agreements include contracts for oncology and cardiology specialty care services in South Carolina and Mississippi[6] - Evolent Health is actively pursuing market expansion and new technology development to enhance service offerings[26] - The company anticipates significant growth in impact throughout the year, focusing on new partner additions and service expansions[45] Risks and Future Outlook - Adjusted EBITDA is expected to improve as the company focuses on operational performance and cost management strategies[28] - Risks include the ability to efficiently integrate NIA into operations and the dependency on key personnel for future growth[47] - The company does not intend to pay cash dividends on its Class A common stock[49] Interest and Shares - The company reported interest income of $2,550,000 in Q1 2024, an increase from $1,060,000 in Q1 2023, while interest expense decreased to $5,997,000 from $12,895,000[41] - The number of weighted-average common shares for basic and diluted earnings per share increased to 114,141,000 in Q1 2024 from 107,783,000 in Q1 2023[43]